Curis, Inc. (CRIS): Price and Financial Metrics


Curis, Inc. (CRIS): $7.77

0.42 (+5.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRIS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

CRIS POWR Grades


  • Growth is the dimension where CRIS ranks best; there it ranks ahead of 58.21% of US stocks.
  • CRIS's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • CRIS ranks lowest in Momentum; there it ranks in the 9th percentile.

CRIS Stock Summary

  • With a one year PEG ratio of 391.99, Curis Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 91.18% of US stocks.
  • CRIS's price/sales ratio is 65.22; that's higher than the P/S ratio of 95.65% of US stocks.
  • In terms of volatility of its share price, CRIS is more volatile than 94.99% of stocks we're observing.
  • Stocks that are quantitatively similar to CRIS, based on their financial statements, market capitalization, and price volatility, are FLDM, CNET, SBBP, ONCT, and MYSZ.
  • CRIS's SEC filings can be seen here. And to visit Curis Inc's official web site, go to www.curis.com.

CRIS Valuation Summary

  • In comparison to the median Healthcare stock, CRIS's price/sales ratio is 1741.67% higher, now standing at 66.3.
  • CRIS's price/sales ratio has moved down 129.2 over the prior 243 months.
  • CRIS's EV/EBIT ratio has moved down 18.7 over the prior 243 months.

Below are key valuation metrics over time for CRIS.

Stock Date P/S P/B P/E EV/EBIT
CRIS 2010-07-16 7.4 2.1 -18.0 -16.2
CRIS 2009-07-10 7.0 2.2 -11.4 -10.1
CRIS 2006-09-26 6.5 1.9 -5.3 -3.7
CRIS 2005-06-21 53.8 4.1 -12.8 -12.2
CRIS 2005-01-13 48.9 6.7 -10.8 -10.8
CRIS 2002-11-25 29.7 4.4 -0.2 -0.2

CRIS Growth Metrics

  • Its 4 year price growth rate is now at -90.58%.
  • Its 5 year revenue growth rate is now at 40.72%.
  • Its 2 year net income to common stockholders growth rate is now at 33.85%.
CRIS's revenue has moved down $620,000 over the prior 30 months.

The table below shows CRIS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 10.315 -29.902 -30.126
2020-12-31 10.835 -25.739 -29.908
2020-09-30 11.098 -25.623 -30.999
2020-06-30 11.212 -27.628 -31.461
2020-03-31 10.946 -24.617 -31.966
2019-12-31 10.004 -26.205 -32.141

CRIS Price Target

For more insight on analysts targets of CRIS, see our CRIS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.00 Average Broker Recommendation 1.5 (Moderate Buy)

CRIS Stock Price Chart Interactive Chart >

Price chart for CRIS

CRIS Price/Volume Stats

Current price $7.77 52-week high $17.40
Prev. close $7.35 52-week low $0.90
Day low $7.37 Volume 1,264,700
Day high $7.91 Avg. volume 2,818,162
50-day MA $9.83 Dividend yield N/A
200-day MA $8.38 Market Cap 711.23M

Curis, Inc. (CRIS) Company Bio


Curis, Inc. engages in the discovery and development of drug candidates for the treatment of human cancers. The company was founded in 2000 and is based in Lexington, Massachusetts.


CRIS Latest News Stream


Event/Time News Detail
Loading, please wait...

CRIS Latest Social Stream


Loading social stream, please wait...

View Full CRIS Social Stream

Latest CRIS News From Around the Web

Below are the latest news stories about Curis Inc that investors may wish to consider to help them evaluate CRIS as an investment opportunity.

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 1, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 259,550 shares of Curis common stock to fifteen new employees, with a grant date of July 1, 2021 (the "Q3 2021 Inducement Grants").

Yahoo | July 7, 2021

Hedge Funds Have Never Been This Bullish On Curis, Inc. (CRIS)

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […]

Yahoo | July 6, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS

NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Curis, Inc. (“Curis” or the “Company”) (NASDAQ: CRIS). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The investigation concerns whether Curis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On June 1

Yahoo | June 28, 2021

Curis, Inc. Set to Join Russell 2000®, 3000® and Microcap® Indexes

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it will be added to the Russell 2000®, 3000® and Microcap® indexes at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

Yahoo | June 25, 2021

Is Anavex Life Sciences Corp. (AVXL) A Good Stock To Buy?

The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31st. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]

Yahoo | June 21, 2021

Read More 'CRIS' Stories Here

CRIS Price Returns

1-mo -0.26%
3-mo -28.32%
6-mo -25.65%
1-year 516.67%
3-year 365.27%
5-year -7.50%
YTD -5.13%
2020 381.76%
2019 146.38%
2018 -80.29%
2017 -77.27%
2016 5.84%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9232 seconds.